The Spark Investment Management LLC Invests $374,000 in CytomX Therapeutics, Inc. (CTMX)

The Spark Investment Management LLC Invests $374,000 in CytomX Therapeutics, Inc. (CTMX)

Spark Investment Management LLC purchased a new stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 23,904 shares of the company’s stock, valued at approximately $374,000. Spark Investment Management LLC owned about 0.07% of CytomX Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of CTMX. Candriam Luxembourg S.C.A. increased its position in shares of CytomX Therapeutics by 59.5% in the second quarter. Candriam Luxembourg S.C.A. now owns 67,000 shares of the company’s stock valued at $684,000 after buying an additional 25,000 shares during the period. Bank of New York Mellon Corp increased its position in shares of CytomX Therapeutics by 208.4% in the second quarter. Bank of New York Mellon Corp now owns 71,738 shares of the company’s stock valued at $733,000 after buying an additional 48,474 shares during the period. California State Teachers Retirement System increased its position in shares of CytomX Therapeutics by 164.0% in the second quarter. California State Teachers Retirement System now owns 42,830 shares of the company’s stock valued at $438,000 after buying an additional 26,607 shares during the period. Swiss National Bank acquired a new position in shares of CytomX Therapeutics during the second quarter valued at $230,000. Finally, Emerald Acquisition Ltd. acquired a new position in shares of CytomX Therapeutics during the second quarter valued at $446,000. Institutional investors own 54.19% of the company’s stock.

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) traded up 0.26% during mid-day trading on Wednesday, hitting $11.45. 108,493 shares of the stock traded hands. The company’s market cap is $416.80 million. The stock has a 50-day moving average of $11.46 and a 200-day moving average of $12.05. CytomX Therapeutics, Inc. has a 52 week low of $9.10 and a 52 week high of $17.79.

Several brokerages have recently issued reports on CTMX. Zacks Investment Research raised shares of CytomX Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 price objective for the company in a research note on Wednesday, January 4th. Cann reissued a “buy” rating on shares of CytomX Therapeutics in a research note on Tuesday, December 6th. Oppenheimer Holdings, Inc. reissued a “buy” rating on shares of CytomX Therapeutics in a research note on Wednesday, December 14th. Finally, Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a research note on Monday, December 5th. Three analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $17.67.

In related news, Director Timothy M. Shannon sold 33,064 shares of the firm’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $11.48, for a total transaction of $379,574.72. Following the completion of the sale, the director now directly owns 268 shares in the company, valued at $3,076.64. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, Director Ix L.P. Canaan sold 13,730 shares of the firm’s stock in a transaction that occurred on Wednesday, November 9th. The stock was sold at an average price of $11.03, for a total transaction of $151,441.90. The disclosure for this sale can be found here. Corporate insiders own 4.70% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets.

Want to see what other hedge funds are holding CTMX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CytomX Therapeutics, Inc. (NASDAQ:CTMX).

Related posts

Leave a Comment